Prosecution Insights
Prosecution Insights
12 pending office actions • 11 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 31 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (33%) |
| §102 only | 1 (8%) |
| §112 only | 2 (17%) |
| Double-patenting + other | 1 (8%) |
| No statute on record | 4 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DICKINSON, PAUL W | 1 | 63.0% | +9.5% |
| RAO, PADMAJA S | 1 | 69.5% | +35.9% |
| CORDAS, EMILY ANN | 1 | 50.6% | +58.5% |
| FETTEROLF, BRANDON J | 1 | 49.5% | +14.6% |
| VISHNYAKOVA, ELENA VLADIMIROVNA | 1 | 59.3% | +73.3% |
| ROGERS, ERIC JASON | 1 | 59.2% | +28.6% |
| O DELL, DAVID K | 1 | 57.8% | +35.8% |
| HOWELL, THEODORE R | 1 | 66.8% | +25.4% |
| BATES, KEENAN ALEXANDER | 1 | 46.3% | +70.8% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17560680 | ENHANCED DIFFERENTIATION OF BETA CELLS | NGUYEN, NGHI V | 86d overdue |
| 18566176 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | RAO, PADMAJA S | 52d overdue |
| 17669874 | PANCREATIC DIFFERENTIATION | BATES, KEENAN ALEXANDER | 37d overdue |
| 17916484 | INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | O DELL, DAVID K | 31d overdue |
| 17820773 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS | HOWELL, THEODORE R | 25d overdue |
| 18030518 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VISHNYAKOVA, ELENA VLADIMIROVNA | 7d |
| 18248068 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | FETTEROLF, BRANDON J | 28d |
| 18018787 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | ROGERS, ERIC JASON | 28d |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1618 | 1 |
| 1627 | 1 |
| 1632 | 1 |
| 1691 | 1 |
| 1638 | 1 |
| 1621 | 1 |
| 1628 | 1 |
| 1631 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647137 | STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION | DICKINSON, PAUL W | 1618 | §103 | Non-Final OA | 26d overdue | Pending | Apr 26, 2024 |
| 18566176 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | RAO, PADMAJA S | 1627 | Other | Non-Final OA | 52d overdue | Pending | Dec 01, 2023 |
| 18281154 | STEM CELL DIFFERENTIATION AND POLYMERS | CORDAS, EMILY ANN | 1632 | DPOther | Non-Final OA | 71d | Pending | Sep 08, 2023 |
| 18248068 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | FETTEROLF, BRANDON J | 1626 | §112 | Final Rejection | 28d | Pending | Apr 06, 2023 |
| 18030518 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VISHNYAKOVA, ELENA VLADIMIROVNA | 1691 | §103 | Non-Final OA | 7d | Pending | Apr 06, 2023 |
| 18018787 | IN VITRO DIFFERENTIATION OF PANCREATIC ENDOCRINE CELLS | ROGERS, ERIC JASON | 1638 | §102 | Non-Final OA | 28d | Pending | Jan 30, 2023 |
| 17916484 | INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | O DELL, DAVID K | 1621 | Other | Non-Final OA | 31d overdue | Pending | Sep 30, 2022 |
| 17820773 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | 25d overdue | Pending | Aug 18, 2022 |
| 17669874 | PANCREATIC DIFFERENTIATION | BATES, KEENAN ALEXANDER | 1631 | §112 | Final Rejection | 37d overdue | Pending | Feb 11, 2022 |
| 17560680 | ENHANCED DIFFERENTIATION OF BETA CELLS | NGUYEN, NGHI V | 1653 | §103 | Non-Final OA | 86d overdue | Pending | Dec 23, 2021 |
| 17345256 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | CHICKS, ASHLI ARIANA | 1626 | Other | Non-Final OA | 18d overdue | Pending | Jun 11, 2021 |
| 16845280 | GENE-EDITING SYSTEMS FOR MODIFYING A SCN9A OR SCN10A GENE AND METHODS OF USE THEREOF | SHIN, DANA H | 1635 | §103 | Final Rejection | 49d overdue | Pending | Apr 10, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial